Regions With Risk Of
Malaria (C)
<
Cambodia
Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country except in the Phnom Penh area and close around Tonle Sap. Malaria does, however, occur in the tourist area of Angkor Wat. P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported. Resistance to mefloquine reported in western provinces near the Thai border.
Camaroon
Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. P. falciparum resistant to chloroquine and sulfadoxine–pyrimethamine reported.
Cape Verde
Limited malaria risk exists from September through November in São Tiago Island.
Central African Rebublic
Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. Resistance to chloroquine and sulfadoxine–pyrimethamine reported.
Chad
Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. Resistance to chloroquine reported.
China
Malaria risk—including P. falciparum malaria—occurs in Hainan and Yunnan. Multidrug-resistant P. falciparum has been reported. Risk of P. vivax malaria exists in Fujian, Guangdong, Guangxi, Guizhou, Hainan, Sichuan, Xizang (only along the valley of the Zangbo river in the extreme south-east) and Yunnan. Very low malaria risk (P. vivax only) exists in Anhui, Hubei, Hunan, Jiangsu, Jiangxi and Shandong. The risk may be higher in areas of focal outbreaks. Where transmission exists, it occurs only in remote rural communities below 1500 m: from July to November north of latitude 33°N, from May to December between 33°N and 25°N, and throughout the year south of 25°N. There is no malaria risk in urban areas nor in the densely populated plain areas. In general, tourists do not need to take malaria prophylaxis unless they plan to stay in remote rural areas in the provinces listed above.
Columbia
Malaria risk—P. falciparum (45%), P. vivax (55%)—is high throughout the year in rural/jungle areas below 800 m, especially in municipalities of the regions of Amazonia, Orinoquía, Pacífico and Urabá-Bajo Cauca. Transmission intensity varies from department to department, with the highest risk in Amazonas, Chocó, Córdoba, Guainía, Guaviare, Putumayo and Vichada. Chloroquine-resistant P. falciparum exists in Amazonia, Pacífico and Urabá-Bajo Cauca. Resistance to sulfadoxine–pyrimethamine reported.
Comoros
Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. Resistance to chloroquine reported.
Congo
Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. Resistance to chloroquine and sulfadoxine-pyrimethamine reported.
Congo, Democratic Rebublic of the (formerly Zaire)
Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. Resistance to chloroquine and sulfadoxine–pyrimethamine reported.
Costa Rica
Malaria risk-—almost exclusively due to P. vivax—is moderate throughout the year in the cantons of Los Chiles (Alajuela Province) and Matina and Talamanca (Limón Province). Lower transmission risk exists in cantons in the provinces of Alajuela, Guanacaste and Heredia, and in other cantons in Limón Province. Negligible or no risk of malaria transmission exists in the other cantons of the country.
Cote d'Ivoire
Malaria risk—predominantly due to P. falciparum—exists throughout the year in the whole country. Resistance to chloroquine and sulfadoxine–pyrimethamine reported.
| A - B | C | D - G | H - L | M - O | P - S | T - Z | Return to the country list |
World Health Organization. International Travel and Health 2003. Geneva, Switzerland.

Important Information
There are four types of malaria. MALARONE is approved for the treatment and prevention of Plasmodium falciparum malaria in adults and children weighing at least 25 lbs.
In studies conducted for the prevention of malaria in adults, the most common side effects possibly attributed to MALARONE versus placebo were headache (5% vs. 7%) and abdominal pain (3% vs. 5%), in pediatric patients, headache (14% vs. 14%), abdominal pain (31% vs. 29%), and vomiting (7% vs. 6%).
MALARONE is not for everyone. You should not take MALARONE if you have severe kidney disease or are allergic to MALARONE or any of its components. If you are pregnant, consult your physician about the risks and benefits of using MALARONE. Rare cases of anaphylaxis following treatment with atovaquone/proguanil (MALARONE) have been reported.









